OPKO Health to report Q1 results on April 30, 2025.
ByAinvest
Thursday, Apr 17, 2025 8:08 am ET1min read
OPK--
Investors and financial professionals are encouraged to pre-register for the call to gain immediate access. The conference call number is 833-630-0584 for U.S. participants and 412-317-1815 for international participants. The webcast will be available on OPKO's Investor Relations page and at the provided link. A telephone replay will be available later.
OPKO Health has been active in the market, recently announcing a $100 million increase to its existing share repurchase program, bringing the aggregate capacity to $200 million [2]. The company's significant insider ownership, with 52% of the shares owned by insiders, indicates strong confidence in the company's future growth and expansion [3]. OPKO Health has also entered into a collaboration agreement with Entera Bio to advance an oral GLP-1/glucagon tablet candidate into the clinic for treating obesity and metabolic disorders [4].
The company's recent financial performance has shown resilience, with full-year 2024 results beating expectations despite a 17% decline in revenue compared to FY 2023. The company reported a return to profitability, driven by strong pharmaceutical revenue growth and strategic collaborations [5].
For more details about the Q1 2025 earnings call and to register for the webcast, visit OPKO Health's Investor Relations page.
References:
[1] https://finance.yahoo.com/quote/OPK/news/
[2] https://finance.yahoo.com/quote/OPK/news/
[3] https://finance.yahoo.com/quote/OPK/news/
[4] https://finance.yahoo.com/quote/OPK/news/
[5] https://finance.yahoo.com/quote/OPK/news/
• OPKO Health to report Q1 2025 results on April 30, 2025 • Conference call and webcast to discuss results and financial guidance • Pre-register for the call to gain immediate access • Dial 833-630-0584 (U.S.) or 412-317-1815 (International) to participate • Webcast available at OPKO's Investor Relations page and here • Telephone replay to be available later.
OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, has announced that it will release its operating and financial results for the first quarter of 2025 on April 30, 2025. The company's senior management will provide a business update and discuss the results, as well as financial guidance, during a conference call and live audio webcast scheduled to begin at 4:30 p.m. Eastern time on the same day.Investors and financial professionals are encouraged to pre-register for the call to gain immediate access. The conference call number is 833-630-0584 for U.S. participants and 412-317-1815 for international participants. The webcast will be available on OPKO's Investor Relations page and at the provided link. A telephone replay will be available later.
OPKO Health has been active in the market, recently announcing a $100 million increase to its existing share repurchase program, bringing the aggregate capacity to $200 million [2]. The company's significant insider ownership, with 52% of the shares owned by insiders, indicates strong confidence in the company's future growth and expansion [3]. OPKO Health has also entered into a collaboration agreement with Entera Bio to advance an oral GLP-1/glucagon tablet candidate into the clinic for treating obesity and metabolic disorders [4].
The company's recent financial performance has shown resilience, with full-year 2024 results beating expectations despite a 17% decline in revenue compared to FY 2023. The company reported a return to profitability, driven by strong pharmaceutical revenue growth and strategic collaborations [5].
For more details about the Q1 2025 earnings call and to register for the webcast, visit OPKO Health's Investor Relations page.
References:
[1] https://finance.yahoo.com/quote/OPK/news/
[2] https://finance.yahoo.com/quote/OPK/news/
[3] https://finance.yahoo.com/quote/OPK/news/
[4] https://finance.yahoo.com/quote/OPK/news/
[5] https://finance.yahoo.com/quote/OPK/news/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet